OBJECTIVE: Up to 32% of older patients take less medication than prescribed to avoid costs, yet a comprehensive assessment of risk factors for cost-related nonadherence (CRN) is not available. This review examined the empirical literature to identify patient-, medication-, and provider-level factors that influence the relationship between medication adherence and medication costs.
INTRODUCTION
Cost-related medication nonadherence (CRN) is a common and critical problem for elderly patients in the outpatient setting who take, on average, 4 to 5 different medications each week. 1 Recent surveys show that up to 32% of older adults take less medication than prescribed to avoid costs. [2] [3] [4] Patients who reduce medical costs by taking their medications sporadically, splitting pills, or delaying refills do not achieve the full therapeutic benefits of therapy and may be at increased risk of declining health. 3 Although several studies 5, 6 have reviewed the evidence for linking medication costs to medication adherence, information on which patients are at-risk for CRN is limited. Research shows that individuals with apparently similar financial resources respond differently to medication costs: some will decrease adherence after modest increases in out-of-pocket costs, 7 others will cut back if the increase is large, 8 and still, a third group will steadfastly adhere to therapy despite substantial cost increases. 9 It is yet unclear why economic burden alone does not predict patient susceptibility to cost-related nonadherence. This oversight is particularly urgent, as most enrollees in the standard Medicare Part D drug plan will pay out-of-pocket between 42 and 69% of their total drug expenses each year, and the consequences on medication adherence are yet unknown. 10 The objective of this study was to review the empirical literature on the risk factors for CRN. Previous reviews have not focused on the characteristics of patients who explicitly identify their nonadherence as motivated by cost concerns. This focus is necessary and potentially enlightening, as 2 recent national surveys found that up to 73% of the Medicare population is engaged in drug cost reduction strategies, and 40% report nonadherence, and yet, only 26% report that such nonadherence is related to medication costs. 2, 4 We organized this paper according to a conceptual model developed by Piette et al. 11 specifically for cost-related nonadherence behaviors (see Fig. 1 ). In this model, decisions about CRN are driven by financial pressures and polypharmacy. Secondary effects include characteristics of the medication, mental/physical health, and patient demographics. Clinicians and the health system may mediate the main and secondary effects through such means as fostering patient trust, selecting medications with lower costs, or providing access to cost assistance programs. 11 We applied this model to the empirical literature to assess the evidence for the proposed associations.
METHODS

Search Strategy
We conducted searches of four electronic databases (MED-LINE, CINAHL, Sciences Citations Index Expanded, and EconLit) for English-language articles with empirical data related to medication costs and medication adherence. The review covered the last 5 years of literature ( -October 2006 to coincide with improved measurement of the strategies patients use to avoid medication costs (See Figs. 1 and 2 ). Earlier surveys of CRN asked about only prescription filling problems and did not ask about such behaviors as skipping doses or splitting pills; thus, estimates of CRN were too low.
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For the MEDLINE search, we developed the search strategy, which included the subject heading prescription, drugs in combination with the cost terms personal financing, out-ofpocket costs, economics, ability to pay, deductible, coinsurance, copayment, or cost-sharing; we then applied the terms patient adherence, compliance, drug nonacquisition, or nonadherence.
As primary or review articles were identified, we also manually reviewed the reference lists for additional sources and modified the search terms for the other three databases. Three investi- gators developed the search strategy, 1 (BAB) retrieved the articles and extracted the data, and 3 (BAB, JHG, SBS) made the final selection of studies.
Study Selection
Articles were selected if they met three criteria: (1) reported original study results; (2) used an explicit measure for identifying cost-related nonadherence; and (3) provided results on potential risk factors. The measurement criterion excluded studies that combined all cost-management behaviors (related and unrelated to nonadherence) into a single measure of "cost burden" [13] [14] [15] or derived CRN by estimating the proportion of all medication nonadherence attributable to insurance coverage or income. [16] [17] [18] [19] [20] Those studies are less useful for identifying risk factors, as it is unclear how much of an overlap occurs in the characteristics of individuals who are nonadherent due to cost reasons rather than noncost reasons or who reduce drug costs without taking less medication. In addition, we excluded studies that reported no results on the covariates, as our objective was to assess risk factors. 7, 8, [21] [22] [23] [24] [25] Finally, we limited the review to only studies conducted in the United States.
RESULTS
The electronic search identified 18,961 articles on medication adherence and 2,331 on medication costs, and the combination produced 203 for manual review. Of these, only 51 related to our study objective and 17 met the inclusion criteria. measuring duration of coverage, all found that the protective effect of drug coverage decreased by about half with anything less than full year coverage. Details about the drug benefit design beyond source and duration were studied far less, and the evidence was sometimes inconsistent. Drug plans with a low maximum drug benefit cap (e.g., $200 in total drug costs per quarter) were reexamined in 3 studies, 26, 28, 44 and all three detected a significant risk for CRN with this drug benefit design. Only one study examined how CRN relates to patient knowledge of what the drug coverage actually covers, and it found an association with caps or limits on drug benefits but not with copays. 39 The evidence was strong in 8 of 9 reviewed studies for a substantial increase in the risk of CRN with increased medication costs, independent of having any drug coverage. For instance, among 912 persons with diabetes in the Veterans Affairs health system, those with monthly out-of-pocket drug costs exceeding $100 were substantially more likely (OR 9.8; CI 5.3-18.2) to reduce medication use due to costs compared to individuals with costs less than $50. 43 In a survey of 4,055 chronically ill individuals, monthly out-of-pocket drug costs exceeding $100 increased the likelihood 5-fold for CRN (OR 5.5; CI 4.0-7.7) relative to costs under $50. 38 In 6 of 7 studies with multivariate models, medication costs emerged as a significant predictor of CRN, even after controlling for drug insurance status. A comparison of multivariate models, both with and without out-of-pocket costs, found that medication costs, rather than insurance coverage, was the stronger predictor of cost-related nonadherence. 36 Income. Income was a strong risk factor for CRN and one of the most consistently tested. Thirteen of the 15 reviewed studies detected a statistically significant (P<.05) risk increase of CRN associated with low income. For instance, in a survey of 1,088 Medicare HMO plan enrollees who reached a benefit limit, the authors observed a 38% reduction in medication use for those with monthly incomes under $1,000 compared to 17% for those with incomes above $4,000 (P<.05). 26 Among 15,998 Medicare 40 Income remained an independent and significant explanatory factor in 10 of 12 multivariate models, after adjustments for health insurance and medication costs.
Patient Characteristics
Socio-Demographics. In the 13 reviewed studies, including demographic measures, most detected mixed or no associations between cost-related medication nonadherence and traditional indicators of vulnerability such as female gender, low education, and minority race, after controlling for income and insurance. The one exception was older age: in 11 of 13 studies, older adults were consistently less likely to engage in CRN than younger adults, after controlling for economic status.
Perceived Risks/Benefits of Therapy. Direct evidence on how patients weigh the benefits of therapy against the risks of nonadherence was limited to one study; however, 5 studies provided indirect evidence suggesting that the risk of CRN increases when patients perceive a negligible consequence. Direct evidence is offered in a study of 1,088 Medicare enrollees where 32% reported cost-related nonadherence, yet only 9% thought their condition had worsened as a result. 26 Indirect evidence may be provided by the finding in 4 of 5 studies that reducing the dose was a more common behavior than forgoing the prescription. It is intuitive that patients would save the most money by omitting entire prescriptions, yet most CRN patients instead tried to make the prescription last longer. This behavior indicates some level of risk-to-benefit decision making. For instance, in a survey of 1,088 Medicare enrollees, 24% skipped doses because of costs, while only 13% did not fill prescriptions. 26 Mental/Physical Health 
Polypharmacy and Medication Characteristics
Contrary to the proposed association in the conceptual model, no relationship emerged between cost-related related medication nonadherence and polypharmacy, as measured by the number of medications prescribed. After multivariate adjustments for patients' health and socioeconomic status, all 5 reviewed studies found no evidence that the risk of costrelated medication nonadherence increased with multidrug regimens. 26, 27, 34, [36] [37] [38] 41 Limited information was available on the types of the medications that exacerbate or ameliorate cost-related nonadherence. Only 3 studies examined the kinds of medications affected by cost-related nonadherence, and none tested the association. For instance, a listing of the top 5 drug classes most affected by CRN showed a wide range of therapeutic importance: HMG Co-A reductase inhibitors, proton pump inhibitors, COX-2 inhibitors, diuretics, and non-sedating antihistamines. 33 In contrast, in 4,055 older adults with chronic illnesses, those who took less medication to reduce costs said it was often the drug taken for medication-sensitive conditions such as asthma, chronic obstructive pulmonary disease, and depression. 34 No clear pattern emerged in these studies of cost-related nonadherence occurring more for essential than for nonessential medications.
Clinician Characteristics
Physician-Patient Relationship. Only 3 reviewed studies assessed the influence of the physician-patient relationship on CRN, and the results varied by measurement method. In the 2 studies using a measure of physician trust or quality, protective associations were detected with high trust at statistically significant levels (P<.05 or less) and in multivariate models. For example, a study of 15,998 Medicare beneficiaries found those who reported the lowest quality physician relationship were at higher risk (OR 2.1; 95% CI 1.4-3.2) of CRN relative to patients with higher quality physician relationships 41 Similarly, in a survey of older patients with diabetes, high physician trust was associated with lower CRN, even after adjusting for high prescription costs and low income. 43 In contrast, the two studies using the number of physician visits found no evidence of a relationship to cost-related nonadherence.
41,42
Prescribed Less Costly Agents or Discussed Costs. Only 3 studies assessed the association between CRN and the prescribing of less costly agents or discussing drug costs and all found increased risk or did not test the relationships for statistical significance. For example, in a cross-sectional survey of health plan members, those who asked their doctor or pharmacist for less costly medications were far more likely to be engaged in cost-related nonadherence of medications than individuals who did not make such requests (41 vs 15%, P<.001) Similarly, the reviewed studies provided only anecdotal evidence on the extent prescribers choosing lessexpensive agents will prevent cost-related nonadherence. For instance, in a study of the medications affected by cost-related nonadherence in 1 health plan, 15 of the top 20 affected medications had generic or over-the-counter substitutes. 33 The authors interpreted this finding as suggestive of missed opportunities to prescribe less costly agents.
DISCUSSION
The findings from a randomized trial 45 and dozens of observational studies indicate that lack of drug coverage strongly inhibits the use of prescription drugs, but there is less information on the other risk factors, especially those unrelated to financial burden. Furthermore, there has been no assessment of whether the risk factors identified for all-cause nonadherence also predict cost-related nonadherence as indicated by patients.
In our review, we found empirical support for concluding that certain patients may be more susceptible to cost-related medication nonadherence than others, regardless of financial burden. Nearly all of the studies were cross-sectional, which limits the interpretation to only associations. Nevertheless, some of the associations remained consistent across different patient groups and in numerous studies with large sample sizes. As others have found, not having prescription drug coverage emerged as a significant and robust risk factor for cost-related nonadherence. However, the protection afforded by drug coverage varied by the source, duration, and to some extent, the benefit design features. Medication costs, rather than drug coverage, was the more influential economic factor on CRN decisions. These findings are supported by studies using only insurance claims, which have shown average medication use decreases after increases in copayments even among people with the same type of drug coverage. 8, 22, 23 The reviewed studies also established consistent links among low levels of physical health, mental health deficits, and CRN, and these effects persisted after controlling for economic factors. Individuals who have symptoms of depression or a heavy disease burden appear to be more susceptible to cost-related nonadherence, and this tendency cannot be explained by lack of drug coverage, poverty status, or monthly out-of-pocket drug costs.
We did not find sufficient evidence that patients fully understand the potential consequences of CRN on their health. To the contrary, the limited evidence suggested that perceptions of low health risk may predict CRN. It remains to be determined why so many patients apparently believe that skipping doses to reduce costs will not compromise the effectiveness of their treatment.
Physician relationships rated by patients as high quality and trustworthy greatly decreased the likelihood of CRN. However, discussions about medication costs with doctors, pharmacists, or nurses appeared as a marker of high risk. This latter finding, though, is likely due to the cross-sectional study designs.
Several limitations of this review should be noted. The assessment of CRN was based on self-report. In general, patients tend to understate nonadherence so our study populations were probably a subset of the true population. 46 Furthermore, we did not know whether the reported nonadherence conflicted with the advice of prescribers or was trivial (i.e., one skipped dose). The cross-sectional study designs also confounded some of the findings and interpretations. There are high correlations, for instance, among contemporaneous measures of health status, medication costs, and polypharmacy. Thus, it is unclear if medication costs lead to cost-related nonadherence, which then leads to lower health status or if the causality order begins with worsening health. Lastly, only 2 of the reviewed studies 35, 43 examined patients under the age of 50, thereby, limiting the generalizability of this review to younger populations. Future studies are needed that model the patient response to medication costs using standard measures and accepted theories of health care decision making. One challenge of this review was the wide variety of CRN measures (some without tested reliability and validity). Furthermore, this body of research lacked robust models for explaining the behavior. Piette's conceptual framework for understanding CRN suggests that the response may be modified by multiple contextual factors, but it has never been formally tested. As a result, the studies reviewed here provided uneven coverage of potentially important components of cost-related nonadherence. Also, research on CRN would be improved by more studies of both subjective patient assessments and objective data sources such as administrative insurance claims. It would be valuable to understand the gap between what the drug coverage actually covers and what patients believe it covers.
Lastly, longitudinal studies that track patient perception of risk and financial pressures before the nonadherence decisions are made would provide more valid methods for identifying the most important factors that prompt or prevent CRN. The body of longitudinal research drawn from prescription claims has provided unequivocal evidence of population-level decreases in drug utilization after increases in cost-sharing. 7, 8, 47 The next step is to identify the factors that enabled some patients to maintain their prescription drug regimen despite the cost increases. 10 Moreover, these out-of-pocket costs can vary, as beneficiaries spend through the plan's deductible, coverage gap ("donut-hole"), and catastrophic threshold. 10 Some plans offer alternative benefit designs; however, the majority of Part D enrollees will face substantial and unpredictable medication costs. To put these numbers in context, the median income of households headed by someone aged 65 or older in 2004 was $24,509. 48 Understanding and measuring the risk factors that moderate or exacerbate the impact of medication costs on adherence will be critical for explaining patient responses to the new drug benefit.
